Muscling through AAV immunity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Next-generation muscle-directed gene therapy by in silico vector design.Nature communications · 2019
   Article
2. An optimized gene transfection system in WERI-Rb1 cells.International journal of molecular medicine · 2017
   Article
3. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
   Article
4. Recent advances in lentiviral vector development and applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
   Review

Corrections and comments

• Comment on
  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract